Current Opinion in Cardiology was launched in 1985. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of cardiology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Editor and the Section Editors for this issue.
Robert Roberts was the President and CEO of the University of Ottawa Heart Institute, Canada, (2004–2014) and the Founder and Director of The Ruddy Canadian Cardiovascular Genetics Centre, Canada. He received his M.D. from Dalhousie University, Canada, and completed his residency in internal medicine and fellowship in cardiology at the University of Toronto, Canada. Funded by a Canadian Heart Foundation Scholarship, he pursued research in heart disease at the University of California, USA, followed by a faculty position at Washington University, USA, and Director of the CCU at Barnes Hospital, USA. In 1982 he became Chief of Cardiology at Baylor College of Medicine in Houston, Texas, USA. As a cardiologist, educator and scientist, he developed the MCBK Test, which has been used to diagnose heart attacks for the past three decades. Dr Roberts’ research led him to molecular biology and genetics, during which time he discovered many genes responsible for single gene disorders of the heart. In the past 10 years he has pursued a major effort, which resulted in discovery of the genetic risk variant 9p21 and in collaboration with an international consortium over 50 genetic risk variants for CAD. Dr Roberts is generally regarded as one of the founders of molecular cardiology.
Dr Roberts has had a distinguished and prolific career as a cardiologist, educator and scientist having published over 900 scientific articles. In recognition of his scientific contributions he was elected a Fellow of The Royal Society of Canada in 2013. He has received many awards including the 2012 Research Achievement Award from the Canadian Cardiovascular Society; the 2012 Distinguished Fellowship Award from the International Academy of Cardiology; the McLaughlin Medal from the Royal Society of Canada; the Albrecht Fleckenstein Memorial Award from the International Academy of Cardiology in 2008; Citation for Highly Cited Researcher from ISI Thomson Scientific in 2002; and the Distinguished Scientist Award from the American College of Cardiology in 1998.
David H. Birnie
Dr David H. Birnie was appointed Staff Cardiac Electrophysiologist at the University of Ottawa Heart Institute (UOHI), Canada, in May 2002. He was educated in Scotland and received his medical degree (MB ChB) from Glasgow University, UK, in 1990. After completion of internal medical training at Aberdeen University, UK, he gained his MRCP (UK) in 1993. From 1993, he spent three years as a cardiology research fellow at Glasgow University studying the immunology of atherosclerosis and was awarded his PhD equivalent (MD) in 1996. Between 1996 and 2001, he did cardiology training at Glasgow University and received his Certificate of Completion of Specialist Cardiology Training in 2001. In addition, he spent a year (1999–2000) as a cardiac electrophysiology fellow at the Ottawa Heart Institute, Canada. Dr Birnie is the Director of the Arrhythmia Services at UOHI. His clinical focus is on all aspects of cardiac electrophysiology, including arrhythmia pharmacotherapy and radiofrequency ablation of simple and complex arrhythmias including atrial fibrillation. He also has a major clinical interest in all aspects of implantation and follow-up of device therapy for arrhythmias. He has been involved in over 300 peer-reviewed presentations, publications, and book chapters. His major ongoing research interests are selection and optimization of cardiac resynchronization therapy (CRT) for heart failure patients, investigating optimal strategies for stroke reduction around device surgery/AF ablation and arrhythmias related to cardiac sarcoidosis.
James C. Huhta
Dr Huhta's career has encompassed both clinical education and clinical research. In his field of perinatal cardiology, he has promoted and developed a systematic approach to the assessment of the fetus using ultrasonography. Known as an expert in fetal cardiac failure, he has pushed to understand this unique disease, and dissect the multiple possible causes. His most important achievement has been the development and validation of the Cardiovascular Profile Score. This is now recognized as an evidence-based and rational tool for aiding decisions about treatment for the fetus in distress from a wide range of causes of heart failure.
Former Chief of Cardiology at Children's Hospital of Philadelphia, USA, Daicoff endowed chair-holder at the University of South Florida, USA, and leader in Fetal Cardiology at Mednax Corporation, USA, Dr Huhta continues to evaluate new technology and methods and improve fetal patient management protocols. A pro-life fetal cardiologist, he is committed to the sanctity of life at all ages.